NCT03122132: Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks |
|
|
| Completed | N/A | 200 | Europe | ombitasvir/paritaprevir/ritonavir 8 weeks, viekirax, dasabuvir 8 weeks, exviera | Hepa C | Hepatitis C Infection | 01/18 | 03/18 | | |
HEMATITE, NCT03002818: Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) |
|
|
| Completed | N/A | 41 | Europe | | AbbVie | Chronic Hepatitis C Virus (HCV) | 04/18 | 04/18 | | |
NCT04047680: eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs |
|
|
| Completed | N/A | 441 | RoW | Sofosbuvir / Velpatasvir Oral Tablet, Epclusa, Sofosbuvir and Ledipasvir, Harvoni, Sofosbuvir Tablets, Solvadi, Ombitasvir/paritaprevir/ritonavir, Viekirax/exviera, Elbasvir / Grazoprevir Oral Tablet, Zepatier, Glecaprevir and Pibrentasvir, Maviret | National Taiwan University Hospital | Hepatitis C, Renal Disease, Viral Hepatitis C | 12/18 | 06/19 | | |
